SLC5A2 and Hyperkalemia: Investigator-reported hyperkalemia events (1,119 cases) also showed a lower incidence with SGLT2 inhibitors (hazard ratio, 0.80 [95% CI, 0.68-0.93]; Pheterogeneity = 0.21).